Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo.

Slides:

Advertisements

Similar presentations

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

Advertisements

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia A Randomized, Placebo-controlled Trial (MMM 300) Orgogozo J.M., Rigaud.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment.

High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Discontinuation of medication after nonfatal event: MI

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

LEADER trial: Primary Outcome

TNT: Baseline and final LDL cholesterol levels

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

Differences in awareness, treatment, and control of hypertension between Southerners and non-Southerners Hypertension awareness, treatment, and control.

Baseline characteristics of patients

PREMIER: Rate of hypertension at 18 months

Trial profile John A Dormandy et al. Lancet 2005;366:

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

MACE rate among CAD severity groups (total 0

End point Fenoldopam, n (%) Dopamine, n (%) p

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

(p for noninferiority < 0.001)

Life expectancy and baseline BP: Male participants

Baseline Characteristics

Peter E. Carson et al. JCHF 2015;3:

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.

Baseline Characteristics by hs-CRP

(p for noninferiority = 0.01)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

PROSPER: trial design

Figure 1 Stacked bar chart depicts the proportion of patients with diffusion-weighted imaging (DWI)+ and DWI− scans categorized by index event type TIA.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Baseline characteristics of study population

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

John P. Boehmer et al. JCHF 2017;5:

End point Valsartan Valsartan+HCTZ p

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo Normotensive patients 4.28 3.84 Hypertensive patients 4.90 5.61 Lubsen J et al. J Hypertens 2005, 23:641-648

Angiography/CABG in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Angiography Nifedipine Placebo Normotensive patients 5.44 6.86 Hypertensive patients 5.50 6.53 CABG 1.48 2.19 1.75 1.94 Lubsen J et al. J Hypertens 2005, 23:641-648

Stroke in normotensive and hypertensive patients at baseline (events per 100 patient- years of follow-up) Any stroke or TIA Nifedipine Placebo Normotensive patients 0.71 0.97 Hypertensive patients 1.31 1.81 Debilitating stroke 0.30 0.26 0.52 0.77 Lubsen J et al. J Hypertens 2005, 23:641-648

New overt heart failure in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) New overt heart failure Nifedipine Placebo Normotensive patients 0.43 0.50 Hypertensive patients 0.49 0.78 Lubsen J et al. J Hypertens 2005, 23:641-648